Zum Artikel

Dr. Bernd Goergen Partner

Dr. Bernd GoergenPartner

Dr. Bernd Goergen

Partner

About me

Team Life Sciences & Chemistry, Partner
at HTGF since 2008
my focus Life Sciences & Chemie
my background F&E, Marketing, Investment Banking

CV

Dr Bernd Goergen, Partner, has been a part of High-Tech Gründerfonds’ Life Science Team since early 2008. He holds a PhD in biology and is a certified biotech analyst with the German Association for Financial Analysis and Asset Management (DVFA). He brings with him five years of research experience in the field of virology and immunology and seven years in international diagnostics marketing for German and international companies. Between 2000 and 2007, Dr Goergen also acquired extensive knowledge in M&A and capital market deals while working in the investment banking division of a major German bank.

Four questions for …

Which metaphor do you like to use to describe your job?

Dr. Bernd Goergen

HTGF is like the “Sendung mit der Maus”, 24 hours long. Extremely interesting, extremely exhausting. You have to be a believer to keep it up for long.

What is special about your work at a venture capitalist?

Dr. Bernd Goergen

The enormous trust that founders place in us every day. And: turning today’s dreams into tomorrow’s reality.

What has changed for the better in the past five years?

Dr. Bernd Goergen

There are many more success stories than before. More lighthouses that startups can use as a guide. That inspires and encourages.

What has been your biggest success?

Dr. Bernd Goergen

To have accompanied a drug against a serious disease from the preclinical stage to the market as a seed investor. Our 1st unicorn. The MYR. 2021.

Social Media & contact

My success stories in the HTGF portfolio

12 of 500 Companies
2017

neotiv

Digital Health

neotiv is a spin-off of the Otto von Guericke University in the German city of Magdeburg in close collaboration with the Magdeburg site of the German Centre for Neurodegenerative Diseases …

to neotiv
2010

PEPperPRINT

R&D Tools

PEPperPRINT produces customized ultra-high density peptide microarrays and uses individualized peptide libraries for drug development, antibody characterization, and protein biomarker discovery.

to PEPperPRINT
2008

HAPILA

Industrial Biotech

Hapila’s counter-current crystallisation process provides a cost effective procedure for purification of active pharmaceutical ingredients, completed by experience in synthesis and particle design.

to HAPILA

Guided to exit

12 of 500 Companies
2014

Cunesoft

Exit
Regulatory

Cunesoft provides pioneering online regulatory software for the life sciences and other regulated industries. The SaaS (Software as a Service) based solutions are delivered fully functional to customers and fulfill …

to Cunesoft
2011

MYR

Exit
Pharmaceuticals

First-in-class Entry-Inhibitor for the treatment of chronic hepatitis Delta

to MYR
2009

Humedics

Exit
Patient Monitoring

Humedics markets a system for bedside and instantaneous measurement of liver function. Patented device, consumables and a diagnostic drug allow an optimal market offering.

to Humedics
2009

Fiagon

Exit
Imaging & Navigation

Fiagon develops a new medical navigation system for intraoperative process control and positioning of instruments for ENT, head-/ neck- and neurosurgery.

to Fiagon
2010

ChromoTek

Exit
R&D Tools

ChromoTek focuses on the discovery and development of innovative fluorescent nanoprobes derived from single-chain antibodies from Camelidae (Chromobodies) for applications in research and high-content screening.

to ChromoTek

Recent posts

Last update 23 hours ago